Despite the advances in the treatment of luminal breast cancers, progress has been hampered by a significant deficit in murine models that fully reproduce the hormonal responsiveness and dependency of human ERα+/PR+ breast cancers [5-8] and that can be used to develop better methods to follow the disease after treatment. This evidence concerns the gene PGR and breast carcinoma.